Pear Therapeutics Statistics
Total Valuation
PEARQ has a market cap or net worth of $142. The enterprise value is -$20.49 million.
| Market Cap | 142 |
| Enterprise Value | -20.49M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.10% |
| Owned by Institutions (%) | 0.01% |
| Float | 125.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 1.27.
| Current Ratio | 1.48 |
| Quick Ratio | 1.34 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.40 |
Financial Efficiency
Return on equity (ROE) is -130.50% and return on invested capital (ROIC) is -177.64%.
| Return on Equity (ROE) | -130.50% |
| Return on Assets (ROA) | -57.00% |
| Return on Capital (ROIC) | -177.64% |
| Revenue Per Employee | $63,470 |
| Profits Per Employee | -$377,455 |
| Employee Count | 200 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | 6.98 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 14.25 |
| Average Volume (30 Days) | n/a |
Short Selling Information
| Short Interest | 3.43M |
| Short Previous Month | 1.70M |
| Short % of Shares Out | n/a |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 2.33 |
Income Statement
In the last 12 months, PEARQ had revenue of $12.69 million and -$75.49 million in losses. Loss per share was -$0.54.
| Revenue | 12.69M |
| Gross Profit | 4.51M |
| Operating Income | -123.35M |
| Pretax Income | -75.49M |
| Net Income | -75.49M |
| EBITDA | -65.90M |
| EBIT | -71.60M |
| Loss Per Share | -$0.54 |
Balance Sheet
The company has $59.34 million in cash and $38.85 million in debt, giving a net cash position of $20.49 million.
| Cash & Cash Equivalents | 59.34M |
| Total Debt | 38.85M |
| Net Cash | 20.49M |
| Net Cash Per Share | n/a |
| Equity / Book Value | 30.59M |
| Book Value Per Share | n/a |
| Working Capital | 23.52M |
Cash Flow
In the last 12 months, operating cash flow was -$113.90 million and capital expenditures -$3.47 million, giving a free cash flow of -$117.37 million.
| Operating Cash Flow | -113.90M |
| Capital Expenditures | -3.47M |
| Free Cash Flow | -117.37M |
| FCF Per Share | -$0.85 |
Margins
Gross margin is 35.54%, with operating and profit margins of -971.72% and -594.70%.
| Gross Margin | 35.54% |
| Operating Margin | -971.72% |
| Pretax Margin | -594.70% |
| Profit Margin | -594.70% |
| EBITDA Margin | -519.12% |
| EBIT Margin | -564.04% |
| FCF Margin | -924.57% |
Dividends & Yields
PEARQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.39% |
| Shareholder Yield | -22.39% |
| Earnings Yield | -53,162,676.06% |
| FCF Yield | -82,651,408.45% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PEARQ has an Altman Z-Score of -6.81 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.81 |
| Piotroski F-Score | 2 |